Sofwave Medical reported a strong first quarter for fiscal 2026, with revenue rising 46% year-over-year to $24.4 million and net income turning positive at $1.3 million under IFRS. The company saw a 56% increase in recurring usage fees, reflecting growing adoption of its non-invasive aesthetic treatments, especially among patients using GLP-1 therapies. Gross margin remained robust at 75%, and operating expenses as a percentage of revenue decreased, signaling improved efficiency. With nearly 2,900 systems sold and over 865,000 treatments performed, Sofwave is capitalizing on rising demand for regenerative aesthetic solutions and plans to continue expanding its global market presence.
Alamar Biosciences presented extensive data from its NULISA platform at the AAIC 2026 conference, highlighting advances in blood-based biomarkers for Alzheimer's detection and staging. The company emphasized new findings on eMTBR-Tau and BD-pTau217, ...
Alamar Biosciences announced that its NULISA platform was prominently featured in over 140 scientific presentations at the 2026 Alzheimer's Association International Conference (AAIC) in London, highlighting its growing adoption in Alzheimer's resear...
Holtec Nuclear Corporation has filed a registration statement with the U.S. SEC for a proposed initial public offering (IPO) of its Class A common stock, planning to list on Nasdaq under the symbol "HNUC." The offering details, including share count ...
XRP's supply held on centralized exchanges has dropped to its lowest level in seven years, indicating reduced near-term sell pressure as holders move tokens to self-custody wallets. Despite this positive supply-side signal, XRP's price remains weak, ...
Maple Finance's SYRUP token surged 14% following significant growth in assets under management, reaching $4.6 billion in H1 2026, an 81% increase year-on-year. The rise is driven by strong capital inflows, especially into syrupUSDG, a stablecoin prod...
